IL131025A0 - Treatment of autoimmune disease using tolerization in combination with methotrexate - Google Patents

Treatment of autoimmune disease using tolerization in combination with methotrexate

Info

Publication number
IL131025A0
IL131025A0 IL13102598A IL13102598A IL131025A0 IL 131025 A0 IL131025 A0 IL 131025A0 IL 13102598 A IL13102598 A IL 13102598A IL 13102598 A IL13102598 A IL 13102598A IL 131025 A0 IL131025 A0 IL 131025A0
Authority
IL
Israel
Prior art keywords
tolerization
methotrexate
treatment
combination
autoimmune disease
Prior art date
Application number
IL13102598A
Other languages
English (en)
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Publication of IL131025A0 publication Critical patent/IL131025A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
    • B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
    • B41J2/01—Ink jet
    • B41J2/21—Ink jet for multi-colour printing
    • B41J2/2107—Ink jet for multi-colour printing characterised by the ink properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0094—Colour printing
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0097—Printing on special media, e.g. labels, envelopes
IL13102598A 1997-01-24 1998-01-26 Treatment of autoimmune disease using tolerization in combination with methotrexate IL131025A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3672297P 1997-01-24 1997-01-24
PCT/US1998/001648 WO1998032451A1 (en) 1997-01-24 1998-01-26 Treatment of autoimmune disease using tolerization in combination with methotrexate

Publications (1)

Publication Number Publication Date
IL131025A0 true IL131025A0 (en) 2001-01-28

Family

ID=21890248

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13102598A IL131025A0 (en) 1997-01-24 1998-01-26 Treatment of autoimmune disease using tolerization in combination with methotrexate

Country Status (10)

Country Link
EP (1) EP0994717A4 (de)
JP (1) JP2001511134A (de)
KR (1) KR20000070460A (de)
AU (1) AU6648898A (de)
BR (1) BR9807112A (de)
CA (1) CA2278152A1 (de)
HU (1) HUP0001960A2 (de)
IL (1) IL131025A0 (de)
NO (1) NO993600L (de)
WO (1) WO1998032451A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040103930A (ko) 2002-02-11 2004-12-09 앤태어스 파머, 인코퍼레이티드 피내 주사기
BRPI0614025A2 (pt) 2005-01-24 2012-12-25 Antares Pharma Inc injetores de jato
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
US8251947B2 (en) 2006-05-03 2012-08-28 Antares Pharma, Inc. Two-stage reconstituting injector
US9144648B2 (en) 2006-05-03 2015-09-29 Antares Pharma, Inc. Injector with adjustable dosing
EP2268342B1 (de) 2008-03-10 2015-09-16 Antares Pharma, Inc. Injektionsgerät-sicherheitsvorrichtung
JP5611208B2 (ja) 2008-08-05 2014-10-22 アンタレス・ファーマ・インコーポレーテッド 多数回服用量の注射装置
AU2010226442A1 (en) 2009-03-20 2011-10-13 Antares Pharma, Inc. Hazardous agent injection system
EP2582373A4 (de) 2010-06-16 2013-10-30 Bruce Chandler May Verwendung von levocetirizin und montelukast bei der behandlung von influenza, erkältungen und entzündungen
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
JP6165786B2 (ja) 2012-03-06 2017-07-19 アンタレス・ファーマ・インコーポレーテッド 離脱力特徴を備える充填シリンジ
CN104487114A (zh) 2012-04-06 2015-04-01 安塔雷斯药品公司 针头辅助喷射注射给予睾酮组合物
WO2013169800A1 (en) 2012-05-07 2013-11-14 Antares Pharma, Inc. Injection device with cammed ram assembly
EP2953667B1 (de) 2013-02-11 2019-10-23 Antares Pharma, Inc. Nadelgestützte düseninjektionsvorrichtung mit reduzierter auslöserkraft
WO2014164786A1 (en) 2013-03-11 2014-10-09 Madsen Patrick Dosage injector with pinion system
WO2014165136A1 (en) 2013-03-12 2014-10-09 Antares Pharma, Inc. Constant volume prefilled syringes and kits thereof
CA2901413A1 (en) 2013-03-13 2014-10-09 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of vasculitis
RU2672871C2 (ru) 2013-03-13 2018-11-20 Инфламматори Респонс Ресёрч, Инк. Применение левоцетиризина и монтелукаста при лечении травматических повреждений
RU2015134423A (ru) * 2013-03-13 2017-04-26 Инфламматори Респонс Ресёрч, Инк. Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств
EP3193875B1 (de) 2014-09-15 2022-02-16 Inflammatory Response Research, Inc. Levocetirizin und montelukast in der behandlung von entzündungsvermittelten störungen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE258065T1 (de) * 1987-06-24 2004-02-15 Brigham & Womens Hospital Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
WO1992004049A1 (en) * 1990-09-06 1992-03-19 Rijksuniversiteit Te Utrecht Inhibitor of lymphocyte response and immune-related disease
BR9306042A (pt) * 1992-02-28 1997-11-18 Autoimmune Inc Método para tratar uma doença auto-immune em um mamifero e formas de dosagens farmacêuticas oral e inalável
WO1996040235A1 (en) * 1995-06-07 1996-12-19 Nexstar Pharmaceuticals, Inc. Method to use superantigens to target subpopulations of t cells
EP0834321B1 (de) * 1995-06-13 2003-05-02 Nippon Meat Packers, Inc. Orales mittel gegen rheumatische arthritis und funktionelles nahrungsmittel

Also Published As

Publication number Publication date
NO993600L (no) 1999-09-23
NO993600D0 (no) 1999-07-23
AU6648898A (en) 1998-08-18
HUP0001960A2 (hu) 2000-10-28
EP0994717A1 (de) 2000-04-26
CA2278152A1 (en) 1998-07-30
BR9807112A (pt) 2001-09-18
EP0994717A4 (de) 2000-07-26
JP2001511134A (ja) 2001-08-07
KR20000070460A (ko) 2000-11-25
WO1998032451A1 (en) 1998-07-30

Similar Documents

Publication Publication Date Title
IL131025A0 (en) Treatment of autoimmune disease using tolerization in combination with methotrexate
EP1024701A4 (de) Verfahren und mittel zur behandlung von autoimmunkrankheiten unter verwendung von hitzeschockproteinen
ZA9710339B (en) Xanthines and their therapeutic use
HUP0004439A3 (en) 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
ZA983452B (en) Substituted pyrrolopyridines useful in the treatment of inflammatory diseases.
IL159785A0 (en) Thienopyrimidinediones and their use in the modulation of autoimmune disease
EP0924983A4 (de) S(-)-tolterodin in der behandlung urinärer und gastrointestinaler störungen
EP0966386A4 (de) Vom menschen fortbewegtes fahrzeug
HUP0102142A3 (en) Use of cyclosporins in the treatment of inflammatory autoimmune diseases
HUP0001276A3 (en) Illuminating body for swimming pools and similar
HK1026096A1 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
IL113303A0 (en) Treatment of autoimmune disease using oral tolerization and/or type I interferon
HU9602751D0 (en) Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines
HUP9900147A3 (en) Therapeutic agents and autoimmune diseases
HK1025954A1 (en) Triptolide derivatives useful in the treatment of autoimmune diseases
EP0797440A4 (de) Die behandlung von autoimmunkrankheiten mit hilfe von 2-aminopurinderivaten
GB9621825D0 (en) Microparticles and their use as therapeutic vehicles
GB9705200D0 (en) Well treatment with particles
IL129460A0 (en) Use of lofexidine in the treatment of behavioral disorders
EP1073459A4 (de) Zusammensetzungen und methoden zur tolerierung in immunkomplex-vermittelten krankheitsverläufen
HUP9902802A3 (en) Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders
AU7262800A (en) Diagnostic and therapeutic methods in autoimmune disease
EP1020517A4 (de) Ein aus menschlichen chondrozyten abstammendes gen
IL132845A0 (en) Non-myeloablative tolerogenic treatment
GB9706857D0 (en) Car boot seat and table